Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pfizer
Biotech
Pfizer axes ex-Metsera obesity asset and GIPR prospect
Pfizer dropped a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
Nick Paul Taylor
Aug 4, 2026 8:47am
US lawmakers’ focus on China trials risks ‘huge distraction’
Jul 7, 2026 10:30am
Pfizer’s first new ADC from Seagen buy fails ph. 3 NSCLC trial
Jun 23, 2026 7:15am
A 5-month sprint: Inside Pfizer's $10B deal with Innovent
Jun 21, 2026 10:41pm
Fierce Pharma
Eli Lilly is the ‘clear winner’ from ADA, RBC analyst says
Jun 8, 2026 3:12pm
ADA: Pfizer pads case for berobenatide in obesity
Jun 6, 2026 9:29am
